title: Bromocriptine enhances the uptake of (99m)Tc-MIBI in patients with hepatocellular carcinoma.
abstract: (99m)Tc-methoxyisobutyl isonitrile (MIBI) is a suitable transport substrate for the multidrug resistance gene product P-glycoprotein (P-gp) and widely used for tumor imaging. Bromocriptine has been shown to inhibit the ATPase activity and the function of P-gp. We hypothesized that bromocriptine could promote the accumulation of MIBI by inhibiting P-gp activities, a feature that can be taken advantage of for enhancing (99m)Tc-MIBI imaging. In the current study, we sought to investigate whether bromocriptine enhanced the uptake of (99m)Tc-MIBI in hepatocellular carcinoma patients. Sixty primary hepatocellular carcinoma patients received (99m)Tc-MIBI single photon emission computer tomgraphy (SPECT) prior to surgery. (99m)Tc-MIBI SPECT was performed 15 and 120 min after injection of 20 mCi (99m)Tc-MIBI, and early uptake, delayed uptake (L/Nd), and washout rate (L/Nwr) of (99m)Tc-MIBI were obtained. In addition, a second (99m)Tc-MIBI SPECT was performed according to the same method 48 h after bromocriptine administration. We found that, prior to bromocriptine administration, significant MIBI uptake in tumor lesions was noted in only 10 (16.7%, 10/60) patients with hepatocellular carcinoma. No significant MIBI uptake was observed in the tumor lesions of the remaining 50 (83.3%, 50/60) hepatocellular carcinoma patients. Following bromocriptine administration, all the patients without apparent MIBI uptake demonstrated significant MIBI uptake on (99m)Tc-MIBI SPECT (P < 0.05). Our findings indicate that bromocriptine enhances the uptake of (99m)Tc-MIBI in patients with hepatocellular carcinoma.
authors.affiliation: Department of Internal Medicine, Jiaonan People's Hospital of Shandong Province, Jiaonan, Shandong 266400, China;
authors.forename: Xiangting
authors.initials: X
authors.lastname: Chai
authors.forename: Qiaoyu
authors.initials: Q
authors.lastname: Liu
authors.forename: Wenyu
authors.initials: W
authors.lastname: Shao
authors.forename: Feng
authors.initials: F
authors.lastname: Zhang
authors.forename: Xuehao
authors.initials: X
authors.lastname: Wang
authors.forename: Hai
authors.initials: H
authors.lastname: Wang
keywords: 99mTc-MIBI; P-glycoprotein; bromocriptine; liver cancer; multidrug resistance
references.citation: Eur J Nucl Med Mol Imaging. 2002 Jul;29(7):876-81
references.pmid: 12111127
references.citation: Ann N Y Acad Sci. 2002 Nov;973:468-71
references.pmid: 12485913
references.citation: Eur J Nucl Med Mol Imaging. 2003 Aug;30(8):1147-54
references.pmid: 12830325
references.citation: Eur J Biochem. 1998 Feb 15;252(1):140-6
references.pmid: 9523723
references.citation: Nucl Med Commun. 2003 Apr;24(4):397-402
references.pmid: 12673168
references.citation: J Nucl Med. 1998 Jan;39(1):91-4
references.pmid: 9443743
references.citation: Eur J Endocrinol. 2003 Sep;149(3):187-93
references.pmid: 12943520
references.citation: Jpn J Cancer Res. 2002 Feb;93(2):209-15
references.pmid: 11856485
references.citation: J Nucl Cardiol. 2002 Sep-Oct;9(5):482-90
references.pmid: 12360128
references.citation: J Neurosurg. 2003 Aug;99(2):397-401
references.pmid: 12924716
references.citation: Clin Neurol Neurosurg. 2003 Jul;105(3):183-7
references.pmid: 12860512
references.citation: Mol Cancer Ther. 2002 Dec;1(14):1327-34
references.pmid: 12516966
references.citation: J Pharmacol Sci. 2003 Jul;92(3):171-7
references.pmid: 12890882
references.citation: Farmaco. 2002 May;57(5):385-415
references.pmid: 12058813
references.citation: Anticancer Res. 2002 Jan-Feb;22(1A):251-6
references.pmid: 12017298
references.citation: Brain Tumor Pathol. 2002;19(1):15-22
references.pmid: 12455884
references.citation: Arch Biochem Biophys. 2002 Oct 1;406(1):65-72
references.pmid: 12234491
references.citation: Biol Pharm Bull. 2002 Dec;25(12):1604-7
references.pmid: 12499648
references.citation: Cancer. 2001 Jul 15;92(2):232-9
references.pmid: 11466674
references.citation: Eur J Nucl Med Mol Imaging. 2002 Mar;29(3):288-94
references.pmid: 12002701
references.citation: World J Gastroenterol. 2004 May 1;10(9):1281-5
references.pmid: 15112342
references.citation: Cancer. 1999 Oct 15;86(8):1470-9
references.pmid: 10526275
references.citation: Int J Oncol. 2002 May;20(5):1049-55
references.pmid: 11956603
references.citation: J Nucl Med. 1999 Nov;40(11):1778-83
references.pmid: 10565770
references.citation: Eur J Pharmacol. 2003 Jul 18;473(1):9-17
references.pmid: 12877932
references.citation: Biochem Biophys Res Commun. 1998 Mar 17;244(2):481-8
references.pmid: 9514944
references.citation: BJU Int. 2002 Dec;90(9):957-64
references.pmid: 12460364
references.citation: Int J Cancer. 1999 Jun 11;81(6):944-50
references.pmid: 10362143
references.citation: J Nucl Med. 1998 Jul;39(7):1191-7
references.pmid: 9669392
references.citation: Eur J Nucl Med Mol Imaging. 2002 Jun;29(6):809-14
references.pmid: 12029556
references.citation: Clin Nucl Med. 1999 Nov;24(11):874-9
references.pmid: 10551471
references.citation: Hum Psychopharmacol. 2000 Mar;15(2):95-101
references.pmid: 12404338
references.citation: Can J Physiol Pharmacol. 2002 Nov;80(11):1054-63
references.pmid: 12489924
references.citation: J Nucl Med. 2001 Oct;42(10):1476-83
references.pmid: 11585860
references.citation: Neurosurgery. 1997 Jun;40(6):1323-32; discussion 1333-4
references.pmid: 9179912